Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.29
MASI's Cash to Debt is ranked higher than
67% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. MASI: 1.29 )
MASI' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 1.29

Equity to Asset 0.64
MASI's Equity to Asset is ranked higher than
71% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. MASI: 0.64 )
MASI' s 10-Year Equity to Asset Range
Min: -1.01   Max: 0.81
Current: 0.64

-1.01
0.81
F-Score: 4
Z-Score: 6.36
M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.78
MASI's Operating margin (%) is ranked higher than
88% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 6.58 vs. MASI: 14.78 )
MASI' s 10-Year Operating margin (%) Range
Min: -13.85   Max: 137.71
Current: 14.78

-13.85
137.71
Net-margin (%) 11.06
MASI's Net-margin (%) is ranked higher than
86% of the 385 Companies
in the Global Medical Devices industry.

( Industry Median: 5.11 vs. MASI: 11.06 )
MASI' s 10-Year Net-margin (%) Range
Min: -14.75   Max: 81.05
Current: 11.06

-14.75
81.05
ROE (%) 19.09
MASI's ROE (%) is ranked higher than
93% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 5.84 vs. MASI: 19.09 )
MASI' s 10-Year ROE (%) Range
Min: 17.28   Max: 40.82
Current: 19.09

17.28
40.82
ROA (%) 13.81
MASI's ROA (%) is ranked higher than
96% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 3.49 vs. MASI: 13.81 )
MASI' s 10-Year ROA (%) Range
Min: -19.03   Max: 140.05
Current: 13.81

-19.03
140.05
ROC (Joel Greenblatt) (%) 76.27
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 394 Companies
in the Global Medical Devices industry.

( Industry Median: 12.36 vs. MASI: 76.27 )
MASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.15   Max: 1358.08
Current: 76.27

51.15
1358.08
Revenue Growth (%) 12.50
MASI's Revenue Growth (%) is ranked higher than
87% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MASI: 12.50 )
MASI' s 10-Year Revenue Growth (%) Range
Min: -19.3   Max: 30.3
Current: 12.5

-19.3
30.3
EBITDA Growth (%) -5.10
MASI's EBITDA Growth (%) is ranked higher than
70% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -1.20 vs. MASI: -5.10 )
MASI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 259.6
Current: -5.1

0
259.6
EPS Growth (%) -5.50
MASI's EPS Growth (%) is ranked higher than
69% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. MASI: -5.50 )
MASI' s 10-Year EPS Growth (%) Range
Min: -33.8   Max: 45.9
Current: -5.5

-33.8
45.9
» MASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

MASI Guru Trades in Q3 2013

Ron Baron 2,043,344 sh (-0.13%)
Pioneer Investments 286,545 sh (-21.79%)
Joel Greenblatt 94,545 sh (-30.91%)
Jim Simons 60,600 sh (-86.75%)
» More
Q4 2013

MASI Guru Trades in Q4 2013

Paul Tudor Jones 7,400 sh (New)
Mario Gabelli 34,000 sh (New)
Pioneer Investments 324,995 sh (+13.42%)
Jim Simons Sold Out
Joel Greenblatt 86,888 sh (-8.1%)
Ron Baron 1,370,014 sh (-32.95%)
» More
Q1 2014

MASI Guru Trades in Q1 2014

Jeremy Grantham 83,400 sh (New)
Paul Tudor Jones 24,500 sh (+231.08%)
Mario Gabelli 90,000 sh (+164.71%)
Pioneer Investments 338,961 sh (+4.3%)
Ron Baron 1,366,477 sh (-0.26%)
Joel Greenblatt 38,676 sh (-55.49%)
» More
Q2 2014

MASI Guru Trades in Q2 2014

Jim Simons 262,235 sh (New)
Joel Greenblatt 73,956 sh (+91.22%)
Paul Tudor Jones 37,000 sh (+51.02%)
Mario Gabelli 122,000 sh (+35.56%)
Jeremy Grantham 88,800 sh (+6.47%)
Pioneer Investments Sold Out
Ron Baron 758,386 sh (-44.5%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-06-30 Reduce -44.5%0.07%$22.03 - $27.9 $ 22.22-10%758386
Joel Greenblatt 2014-06-30 Add 91.22%0.01%$22.03 - $27.9 $ 22.22-10%73956
Mario Gabelli 2014-06-30 Add 35.56%$22.03 - $27.9 $ 22.22-10%122000
Joel Greenblatt 2014-03-31 Reduce -55.49%0.03%$25.37 - $31.88 $ 22.22-22%38676
Mario Gabelli 2014-03-31 Add 164.71%0.01%$25.37 - $31.88 $ 22.22-22%90000
Ron Baron 2013-12-31 Reduce -32.95%0.08%$25.62 - $29.61 $ 22.22-21%1370014
Mario Gabelli 2013-12-31 New Buy0.01%$25.62 - $29.61 $ 22.22-21%34000
Joel Greenblatt 2013-09-30 Reduce -30.91%0.04%$21.55 - $27.04 $ 22.22-10%94545
Meridian Funds 2013-06-30 Add 130.2%0.27%$19.04 - $22.5 $ 22.226%609110
Joel Greenblatt 2013-06-30 Add 34.41%0.03%$19.04 - $22.5 $ 22.226%136838
Meridian Funds 2013-03-31 New Buy0.19%$19.51 - $21.33 $ 22.2210%264600
Joel Greenblatt 2013-03-31 Add 64.59%0.04%$19.51 - $21.33 $ 22.2210%101804
Joel Greenblatt 2012-12-31 Add 30.93%0.02%$20.22 - $24.11 $ 22.223%61854
Joel Greenblatt 2012-09-30 Reduce -50.15%0.08%$21 - $24.87 $ 22.22-3%47242
John Burbank 2012-06-30 Sold Out 0.08%$18.35 - $23.98 $ 22.227%0
Joel Greenblatt 2012-06-30 Add 36.65%0.04%$18.35 - $23.98 $ 22.227%94762
John Burbank 2012-03-31 New Buy0.08%$18.46 - $23.49 $ 22.2210%100000
Joel Greenblatt 2012-03-31 Add 110.46%0.07%$18.46 - $23.49 $ 22.2210%69345
Joel Greenblatt 2011-12-31 Add 74.44%0.03%$17.84 - $22.87 $ 22.228%32950
Joel Greenblatt 2011-09-30 New Buy0.07%$20.96 - $30.91 $ 22.22-12%18889
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 20.50
MASI's P/E(ttm) is ranked higher than
89% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 52.10 vs. MASI: 20.50 )
MASI' s 10-Year P/E(ttm) Range
Min: 16.96   Max: 91.05
Current: 20.5

16.96
91.05
P/B 3.90
MASI's P/B is ranked higher than
56% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. MASI: 3.90 )
MASI' s 10-Year P/B Range
Min: 3.54   Max: 15.2
Current: 3.9

3.54
15.2
P/S 2.30
MASI's P/S is ranked higher than
68% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 3.06 vs. MASI: 2.30 )
MASI' s 10-Year P/S Range
Min: 1.77   Max: 9.79
Current: 2.3

1.77
9.79
EV-to-EBIT 13.37
MASI's EV-to-EBIT is ranked higher than
92% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 35.63 vs. MASI: 13.37 )
MASI' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 117.2
Current: 13.37

6.3
117.2
PEG 102.50
MASI's PEG is ranked higher than
87% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 102.50 )
MASI' s 10-Year PEG Range
Min: 0.38   Max: 577.5
Current: 102.5

0.38
577.5
Shiller P/E 20.20
MASI's Shiller P/E is ranked higher than
94% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 20.20 )
MASI' s 10-Year Shiller P/E Range
Min: 14.04   Max: 31.15
Current: 20.2

14.04
31.15
Current Ratio 1.59
MASI's Current Ratio is ranked higher than
56% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. MASI: 1.59 )
MASI' s 10-Year Current Ratio Range
Min: 1.35   Max: 4.87
Current: 1.59

1.35
4.87
Quick Ratio 1.25
MASI's Quick Ratio is ranked higher than
58% of the 395 Companies
in the Global Medical Devices industry.

( Industry Median: 2.04 vs. MASI: 1.25 )
MASI' s 10-Year Quick Ratio Range
Min: 1.15   Max: 4.34
Current: 1.25

1.15
4.34

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 370.30
MASI's Price/Net Current Asset Value is ranked higher than
58% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 370.30 )
MASI' s 10-Year Price/Net Current Asset Value Range
Min: 9.85   Max: 394.17
Current: 370.3

9.85
394.17
Price/Tangible Book 4.70
MASI's Price/Tangible Book is ranked higher than
62% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. MASI: 4.70 )
MASI' s 10-Year Price/Tangible Book Range
Min: 4.11   Max: 15.3
Current: 4.7

4.11
15.3
Price/DCF (Projected) 1.50
MASI's Price/DCF (Projected) is ranked higher than
86% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 28.60 vs. MASI: 1.50 )
MASI' s 10-Year Price/DCF (Projected) Range
Min: 1.22   Max: 2.5
Current: 1.5

1.22
2.5
Price/Median PS Value 0.70
MASI's Price/Median PS Value is ranked higher than
84% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. MASI: 0.70 )
MASI' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 2.72
Current: 0.7

0.62
2.72
Price/Graham Number 2.10
MASI's Price/Graham Number is ranked higher than
80% of the 418 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. MASI: 2.10 )
MASI' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 5.96
Current: 2.1

1.76
5.96
Earnings Yield (Greenblatt) 7.50
MASI's Earnings Yield (Greenblatt) is ranked higher than
87% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. MASI: 7.50 )
MASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 15.8
Current: 7.5

0.9
15.8
Forward Rate of Return (Yacktman) 3.72
MASI's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. MASI: 3.72 )
MASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.2   Max: 64.3
Current: 3.72

3.2
64.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:3M4.Germany
Masimo Corporation was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. On August 13, 2007, the Company completed its initial public offering. It is a global medical technology company that develops, manufactures and markets noninvasive patient monitoring products that improve patient care. The Company develops, manufactures, and markets a family of noninvasive blood constituent patient monitoring solutions that consists of a monitor or circuit board and its proprietary single-patient use and reusable sensors and cables. In addition, it offers remote monitoring and clinician notification solutions, such as the Masimo Patient SafetyNet. It solutions and related products are based upon the proprietary Masimo SET algorithms. The Company invented Masimo Signal Extraction Technology, or Masimo SET, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate. The Company's Masimo SET platform has addressed many of the previous technology limitations and has been referred to by several industry sources as the gold standard in pulse oximetry. The benefits of Masimo SET have been validated in over 100 independent clinical and laboratory studies. This software-based technology is incorporated into a variety of product platforms depending on its customers' specifications. The Company's Masimo SET MS circuit boards perform all signal processing and other pulse oximetry functions incorporating the Masimo SET platform. It next-generation circuit board is the foundation for the Masimo Rainbow SET Pulse CO-Oximetry platform, utilizing technology licensed from Masimo Labs. The MX circuit boards measure arterial blood oxygen saturation levels and pulse rate, and have the circuitry to enable the measurement of total hemoglobin, oxygen content, carboxyhemoglobin, methemoglobin, PVI, and acoustic respiration rate, along with other potential parameters in the future. The Radical-7 incorporates the MX circuit board, which enables Rainbow SET parameters, and offers three-in-one capability to be used as: a standalone device for bedside monitoring; a detachable, battery-operated handheld unit for easy portable monitoring; and a monitor interface via SatShare, proprietary technology allowing its products to work with certain competitor products, to upgrade existing conventional multi-parameter patient monitors to Masimo SET while displaying Rainbow parameters on the Radical-7 itself. The Rad-87, which also contains Masimo Rainbow SET technology, is a compact, lightweight and easy-to-use device designed specifically for use in less acute settings than the Radical-7. The Rad-8 is a bedside pulse oximeter featuring Masimo SET with a low cost design and streamlined
» More Articles for MASI

Headlines

Articles On GuruFocus.com
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction Oct 23 2014 
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014 
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision Oct 16 2014 
New Clinical Study Presented at the American Society of Anesthesiologists Annual Meeting Shows Benef Oct 15 2014 
Masimo Announces CE Mark of the 11th Rainbow(R) Parameter - ORI(TM), Oxygen Reserve Index(TM) Oct 15 2014 
Newborn Foundation Bestows Masimo CEO Joe Kiani With the Hubert H. Humphrey 'Dawn of Life' Award Oct 15 2014 
Mercy Hospital of Buffalo Expands Use of Masimo Patient SafetyNet(TM) After Pilot Program Shows Redu Oct 15 2014 
Masimo Announces CE Mark of Eve(TM) Newborn Screening Application for Radical-7, an Intuitive Softwa Oct 15 2014 
Retrospective Study of Enhanced Recovery After Surgery Program for Patients Undergoing Colorectal Su Oct 15 2014 
Meridian Funds' Top Five Second Quarter Increases Jul 30 2013 

More From Other Websites
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction... Oct 23 2014
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction... Oct 23 2014
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014
Les nouvelles études cliniques démontrent que le dispositif de contrôle non-invasif de... Oct 16 2014
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision... Oct 16 2014
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision... Oct 16 2014
La nouvelle étude clinique présentée lors du congrès annuel de l'American Society of... Oct 16 2014
New Clinical Study Presented at the American Society of Anesthesiologists Annual Meeting Shows... Oct 15 2014
New Clinical Study Presented at the American Society of Anesthesiologists Annual Meeting Shows... Oct 15 2014
Retrospective Study of Enhanced Recovery After Surgery Program for Patients Undergoing Colorectal... Oct 14 2014
Newborn Foundation Bestows Masimo CEO Joe Kiani With the Hubert H. Humphrey 'Dawn of Life' Award Oct 13 2014
Masimo annonce l'homologation sous marquage CE de sa nouvelle application de dépistage néonatal... Oct 10 2014
Masimo Announces CE Mark of Eve(TM) Newborn Screening Application for Radical-7, an Intuitive... Oct 10 2014
Masimo Gets CE Mark Approval for 11th Rainbow Parameter Oct 08 2014
Masimo annonce la conformité CE du 11e paramètre rainbow(R) : ORI(TM), ou Oxygen Reserve Index(TM) Oct 07 2014
Masimo Announces CE Mark of the 11th Rainbow(R) Parameter - ORI(TM), Oxygen Reserve Index(TM) Oct 07 2014
Philips, Koch Industries, The Duke: Intellectual Property Oct 05 2014
MASIMO CORP Files SEC form 8-K, Other Events Oct 02 2014
Philips Electronics loses $467 million patent verdict to Masimo Oct 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK